Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide CINV Existing and Pipeline Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.6% during the forecast period.
This report presents the market size and development trends by detailing the CINV Existing and Pipeline Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the CINV Existing and Pipeline Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of CINV Existing and Pipeline Drugs industry and will help you to build a panoramic view of the industrial development.
CINV Existing and Pipeline Drugs Market, By Type:
Aloxi (palonosetron)
Zofran Generic (ondansetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
SUSTOL (extended release granisetron injection)
Rolapitant
CINV Existing and Pipeline Drugs Market, By Application:
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Some of the leading players are as follows:
Heron Therapeutics
Helsinn
GlaxoSmithKline
Merck
Tesaro
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 CINV Existing and Pipeline Drugs Market: Technology Type Analysis
-
4.1 CINV Existing and Pipeline Drugs Technology Type Market Share Analysis, 2018 & 2026
-
4.2 CINV Existing and Pipeline Drugs Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Aloxi (palonosetron)
4.3.2 Zofran Generic (ondansetron)
4.3.3 Kytril Generic (granisetron)
4.3.4 Emend (aprepitant)
4.3.5 Akynzeo (netupitant-palonosetron)
4.3.6 SUSTOL (extended release granisetron injection)
4.3.7 Rolapitant
5 CINV Existing and Pipeline Drugs Market: Product Analysis
-
5.1 CINV Existing and Pipeline Drugs Product Market Share Analysis, 2018 & 2026
-
5.2 CINV Existing and Pipeline Drugs Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 CINV Existing and Pipeline Drugs Market: Application Analysis
-
6.1 CINV Existing and Pipeline Drugs Application Market Share Analysis, 2018 & 2026
-
6.2 CINV Existing and Pipeline Drugs Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospitals
6.3.2 Specialty Clinics
6.3.3 Diagnostic Centers Therapeutics
6.3.4 Hospital Pharmacies
6.3.5 Drugstores
7 CINV Existing and Pipeline Drugs Market: Regional Analysis
-
7.1 CINV Existing and Pipeline Drugs Regional Market Share Analysis, 2018 & 2026
-
7.2 CINV Existing and Pipeline Drugs Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Heron Therapeutics
9.1.1 Heron Therapeutics Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Helsinn
9.2.1 Helsinn Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 GlaxoSmithKline
9.3.1 GlaxoSmithKline Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Merck
9.4.1 Merck Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Tesaro
9.5.1 Tesaro Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
The List of Tables and Figures (Totals 76 Figures and 136 Tables)
Figure Aloxi (palonosetron) CINV Existing and Pipeline Drugs market, 2015 - 2026 (USD Million)
Figure Zofran Generic (ondansetron) CINV Existing and Pipeline Drugs market, 2015 - 2026 (USD Million)
Figure Kytril Generic (granisetron) CINV Existing and Pipeline Drugs market, 2015 - 2026 (USD Million)
Figure Emend (aprepitant) CINV Existing and Pipeline Drugs market, 2015 - 2026 (USD Million)
Figure Akynzeo (netupitant-palonosetron) CINV Existing and Pipeline Drugs market, 2015 - 2026 (USD Million)
Figure SUSTOL (extended release granisetron injection) CINV Existing and Pipeline Drugs market, 2015 - 2026 (USD Million)
Figure Rolapitant CINV Existing and Pipeline Drugs market, 2015 - 2026 (USD Million)
Figure Hospitals market, 2015 - 2026 (USD Million)
Figure Specialty Clinics market, 2015 - 2026 (USD Million)
Figure Diagnostic Centers Therapeutics market, 2015 - 2026 (USD Million)
Figure Hospital Pharmacies market, 2015 - 2026 (USD Million)
Figure Drugstores market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America CINV Existing and Pipeline Drugs market, by country, 2015 - 2026 (USD Million)
-
Table North America CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table North America CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table North America CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.S. CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.S. CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Canada CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Canada CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Europe CINV Existing and Pipeline Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Europe CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Europe CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Europe CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.K. CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.K. CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Germany CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Germany CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table France CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table France CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Italy CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Italy CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Spain CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Spain CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific CINV Existing and Pipeline Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table China CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table China CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Japan CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Japan CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table India CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table India CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Latin America CINV Existing and Pipeline Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Latin America CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Latin America CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Latin America CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Brazil CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Brazil CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Mexico CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Mexico CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Argentina CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Argentina CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table MEA CINV Existing and Pipeline Drugs market, by country, 2015 - 2026 (USD Million)
-
Table MEA CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table MEA CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table MEA CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table South Africa CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table South Africa CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria CINV Existing and Pipeline Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria CINV Existing and Pipeline Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria CINV Existing and Pipeline Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Heron Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Helsinn Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Tesaro Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
